External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

External broker reports(aggregated public sources)

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><ul><li>This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.</li><li>While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.</li><li>Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.</li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - The RNA Space Is Heating Up

<ul><li>PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight<br>in terms of capital efficiency.</li><li>Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.</li><li>Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight in terms of capital efficiency.Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - FY24: Clear Line of Sight to Multiple Near-Term Potential Catalysts

<div><ul><li>PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference<br>in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US<br>$1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).</li><li>Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.</li><li><div><div><div><div><p>VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.</p></div></div></div></div></li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US $1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<div><div><div><div><ul><li>PYC reported its 2Q24 result, in line with expectations around R&amp;D spend and progress with clinical and preclinical assets.</li><li>Recall PYC is a clinical stage gene therapy company, with core technology aimed at addressing some of the shortcomings typically associated with certain other pipeline options.</li><li>Early stage data is encouraging in initial human, animal and organ on chip models.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC reported its 2Q24 result, in line with expectations around R&amp;D spend and progress with clinical and preclinical assets.Recall PYC is a clinical stage gene therapy company, with core technology aimed at addressing some of the shortcomings typically associated with certain other pipeline options.Early stage data is encouraging in initial human, animal and organ on chip models.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - 2Q24: In Line, All Eyes on RP11 Data and ADPKD Trial Timing

<div><div><div><div><ul><li>PYC has announced follow-up data from the second patient in its Phase 1/2 study assessing VP-001 for Retinitis Pigmentosa 11 (RP11), a rare blinding eye disease.</li><li>While the program is early in nature, we like the correlated dose response and consistent human, NHP and retina-in-dish data.</li><li>There are a number of anticipated near-term potential catalysts around PYC's clinical and nearing-clinical programs which could provide ongoing opportunities for de-risking value-inflection points.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC has announced follow-up data from the second patient in its Phase 1/2 study assessing VP-001 for Retinitis Pigmentosa 11 (RP11), a rare blinding eye disease.While the program is early in nature, we like the correlated dose response and consistent human, NHP and retina-in-dish data.There are a number of anticipated near-term potential catalysts around PYC's clinical and nearing-clinical programs which could provide ongoing opportunities for de-risking value-inflection points.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - Ticking the Boxes with Two Patients at Four Months with VP-001

Australia

Pyc Therapeutics Limited operates as a pharmaceutical company. The Company develops drugs and medicine for various types of diseases. Pyc Therapeutics serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PYC Therapeutics (PYC AU)

PYC Therapeutics Limited - The RNA Space Is Heating Up

While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general

Canaccord Genuity

PYC Therapeutics Limited - FY24: Clear Line of Sight to Multiple Near-Term Potential Catalysts

Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with...

Canaccord Genuity

PYC Therapeutics Limited - Flash Update

VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the...

Canaccord Genuity

PYC Therapeutics Limited - 2Q24: In Line, All Eyes on RP11 Data and ADPKD Trial Timing

PYC reported its 2Q24 result, in line with expectations around R&D spend and progress with clinical and preclinical assets.

Canaccord Genuity

PYC Therapeutics Limited - Ticking the Boxes with Two Patients at Four Months with VP-001

PYC has announced follow-up data from the second patient in its Phase 1/2 study assessing VP-001 for Retinitis Pigmentosa 11 (RP11), a rare...

Canaccord Genuity

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)